🌟 Product Overview
Ensitrelvir (CAS: 2647530-73-0) is a novel 3CL protease inhibitor developed for the treatment of COVID-19, effectively reducing viral replication by targeting SARS-CoV-2’s main protease. With the molecular formula C₂₂H₁₇ClF₃N₉O₂ and molecular weight 531.9, it is a critical component in oral antiviral therapies, particularly for mild to moderate cases. This compound is widely used in pharmaceutical manufacturing, clinical therapy, and antiviral research, aligning with global efforts to combat emerging viral strains.
✅ Key Advantages
💊 High Purity: ≥99% HPLC-certified quality, ensuring pharmaceutical-grade performance12.
🔬 Stability: Stable at room temperature with a 2-year shelf life under recommended storage conditions13.
📈 Clinical Efficacy: Reduces viral load by ~90% in phase III trials for COVID-19 treatment3.
🧪 Structural Confirmation: Verified via NMR, MS, and chromatographic analysis for batch consistency12.
📌 Applications
• Pharmaceuticals: Key intermediate in COVID-19 oral drug formulations (e.g., S-217622)3.
• Clinical Use: Approved for emergency use in managing SARS-CoV-2 infections23.
• Research: Investigated for broad-spectrum antiviral activity against coronaviruses1.
🔍 Quality Certifications
• Complies with USP/EP standards for impurities (<0.1%), residual solvents, and heavy metals12.
• Batch-specific COA includes purity (≥99%), moisture content (≤0.5%), and single impurity limits12.
• Rigorously tested via HPLC (>98% purity), NMR, and mass spectrometry13.
📈 Market Trends
The global antiviral drug market is projected to grow at 6.5% CAGR (2025–2030), driven by persistent COVID-19 variants and pandemic preparedness. Ensitrelvir holds a strategic position in the antiviral API sector, with accelerated adoption in Asia-Pacific and North America13.
China
